Hepatic stellate cells in liver development, regeneration, and cancer.
By Chunyue Yin, Kimberley J. Evason, K. Asahina, D. Stainier. Journal of Clinical Investigation, 2013
654 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/0317ff47ef55262fd2b2e9aa12ef71035800959c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Ela Elyada
- Xiaoqi Mao
- Jin Xu
- Wei Wang
- Chen Liang
- J. Hua
- Qingcai Meng
- Xianjun Yu
Citations in the corpus
- Fibroblast heterogeneity in the cancer wound (2014, background): “Endothelial-mesenchymal transition (EndMT), a process where endothelial cells down-regulate their CD31 expression and induce expression of FSP-1, is another potential source of CAFs (Zeisberg et al., 2007).”
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “For instance, in liver and pancreatic cancer models, quiescent pancreatic stellate cells (PSCs) and hepatic stellate cells (HSCs) express CAF-like surface markers such as α-SMA upon activation with TGF-β and PDGF, which convert them into activated CAFs [41, 42].”